Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital

Date

14 Sep 2024

Session

Poster session 10

Topics

Clinical Research;  Secondary Prevention/Screening

Tumour Site

Small Cell Lung Cancer;  Non-Small Cell Lung Cancer

Presenters

Emmanuel Grolleau

Citation

Annals of Oncology (2024) 35 (suppl_2): S937-S961. 10.1016/annonc/annonc1606

Authors

E. Grolleau1, J. de Bermont1, L. Groshaeny2, O. Pelton3, S. Couraud1

Author affiliations

  • 1 Rhône, Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, 69002 - Lyon/FR
  • 2 Pneumologie_louis Pradel, Hospices Civils de Lyon, Bron/FR
  • 3 Pneumology - Croix Rousse, Hospices Civils de Lyon, 69004 - Lyon/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1566P

Background

Participation rate in lung cancer screening (LCS) programs is challenging. The ILYAD (Initiative LYonnaise pour l’Amorçage du Dépistage) study main objective is to assess whereas various communication methods may improve participation rate among a population of eligible staffs of Lyon University Hospital (LUH).

Methods

In a previous work, we assessed the number of eligible employees at LUH. 838 peoples among 26,954 staffs were found eligible to LCS according to current French guidelines. We designed an LCS program dedicated to staffs from LHU. We provided specific email address, phone number, and an online tool. We applied three communication methods for participants recruitment. We started with common displays (flyers, posters) and general emailing. Then, we involved managers of the departments identified with high-risk employees and occupational medicine. Finally, we used specially trained nurses to meet the employees in their daily routine.

Results

From September 2022 to May 2024, 144 participants were included, resulting in a participating rate of 17.2%. 85 (59%) were included during the first period (common displays and emails), 17 (12%) during the second (targeting high-risk), and 44 (30%) during the third (face to face meeting). Institutional general emailing appeared as the best way of recruitment. Surprisingly, face-to-face interaction were not very efficient, principally due to people lack of commitment afterward. During this first round of screening, one positive screening lead to the diagnosis of a stage IA adenocarcinoma. Moreover, we diagnosed 14 early COPD (group A and B). Coronary calcifications were identified in 15 cases. 70% participants contacted us through the online tool.

Conclusions

Despite a population of healthcare employees and different communication strategies tested, our results showed a low LCS participation rate. These results enhanced the fact that population adherence to LCS program will be a critical issue to address properly in order to improve screening efficiency.

Clinical trial identification

Sponsor code: 69HCL22_0466; NCT05452200 N° IDRCB: 2022-A01203-40 Approved by ethic committee CPP OUEST III: 23/06/2022.

Editorial acknowledgement

Legal entity responsible for the study

Hospices Civils de Lyon.

Funding

AstraZeneca Volition Transdiag.

Disclosure

S. Couraud: Financial Interests, Personal and Institutional, Funding, consulting fees: AstraZeneca, Amgen, Boehringer Ingelheim, MSD, Novartis, Sanofi, Roche, Pfizer, BMS; Financial Interests, Institutional, Funding: Chugai, Lilly, Takeda, Janssen, Celgene, Transdiag, Volition, Adene, BD Bioscience; Financial Interests, Personal, Other, consulting fees: Health event, MaaT Pharma, Pierre Fabre. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.